Shaykarie Tirado

Experienced Study Coordinator with background managing multiple research studies in diverse scientific disciplines. Proven skills in study protocols, data collection, and participant recruitment. Strengths include effective communication, organization, and ability to meet project deadlines consistently. Previous work has demonstrated significant improvement in study efficiency and participant retention rates.

Register Nurse License-96079

• Protecting Human Research Participants Online Training (PHRP), 01/01/24
• Training for Responsibilities of Shippers/Cargo Agents for Transport of Dangerous Goods (IATA), 01/01/24
• Basic Life Support Program (CPR & AED), 01/01/24
• NIDA: Good Clinical Practice (GCP), 01/01/24

• MK8591B-060: A Phase 2b, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Islatravir (ISL) and Ulonivirine (ULO) Once Weekly in Adults With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily, 01/01/25
• M24-541 A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment, 01/01/24
• ESK-001-017 A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2), 01/01/24
• M20-465 A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms, 01/01/24
• GS-US-563-5925: A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir (B/F/TAF), 01/01/24
• 209639: Phase 2b Multicenter, Randomized, Open-Label Study comparing the Efficacy, Safety, PK and Tolerability of VH3810109, administered Either Intravenously or As A Subcutaneous Infusion with rHuPH20 in Combination with CabLA to Standard of Care In Virologically Suppressed Adults Living with HIV, 01/01/24
• M19-965: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety,Tolerability, and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living with HIV on Stable Antiretroviral Therapy Undergoing Analytical Treatment Interruption, 01/01/24
• Exhale-4 A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 24 Weeks in Participants With Eosinophilic Asthma, 01/01/24
• Exhale-3 A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma., 01/01/23
• M23-716 A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata, 01/01/23
• M23-699: SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE, 01/01/23
• M19-44 A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo, 01/01/23
• CNTO1959PSA3005- A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthritis who had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor Agent, 01/01/22
• EHP-101-SS01 A Phase IIa, Double-Blind, Randomised, Intracohort Placebo-Controlled, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients with Diffuse Cutaneous Systemic Sclerosis., 01/01/22
• J1V-MC-IMMA- A Master Protocol for a Randomized, Placebo-Controlled Clinical Trial of Multiple Interventions for the Treatment of Systemic Lupus Erythematosus (Pro00059195)., 01/01/22
• I5T-MC-AACM- A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease (Pro00054759)., 01/01/22
• M20-466- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs), 01/01/22
• M20-186- A Phase 2, Long-Term Extension (LTE) Study with Elsubrutinib and Upadacitinib Given Alone or Combination (ABBV-599) in Subjects with Moderate to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT), 01/01/22
• M19-130- A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus, 01/01/22
• I4V-MC-JAJA- A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis, 01/01/22
• J1P-MC-KFAJ A Randomized, Double Blind, Placebo Controlled, Phase 2 Study of LY3471851 (NKTR 358) in Adults with Systemic Lupus Erythematosus ISLAND-SLE, 01/01/22
• M16-011-A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1), 01/01/22